Use of n-(4-((3-(2-amino-4-pyrimidinyl)-2-pyridinyl)oxy)phenyl)-4-(4-methyl-2-thienyl)-1-phthalazinamine in combination with histone deacetylase inhibitors for treatment of cancer
US-2015072988-A1 · Mar 12, 2015 · US
Pharmaceutical combinations comprising a histone deacetylase inhibitor and an aurora kinase inhibitor and methods of use thereof
US11357776B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-11357776-B2 |
| Application number | US-201716344886-A |
| Country | US |
| Kind code | B2 |
| Filing date | Oct 27, 2017 |
| Priority date | Oct 28, 2016 |
| Publication date | Jun 14, 2022 |
| Grant date | Jun 14, 2022 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The present disclosure relates to a pharmaceutical combination comprising (a) a histone deacetylase 6 inhibitor and (b) an aurora kinase inhibitor, including combined preparations and pharmaceutical compositions thereof; uses of such combination in the treatment or prevention of cancer; and methods of treating or preventing cancer in a subject comprising administering a therapeutically effective amount of such combination.
First claim
Opening claim text (preview).
The invention claimed is: 1. A method for treating or preventing lymphoma in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of (a) a histone deacetylase 6 (HDAC6) inhibitor having the formula: or a pharmaceutically acceptable salt thereof, (b) the aurora kinase inhibitor is alisertib, or a pharmaceutically acceptable salt thereof. 2. The method of claim 1 , wherein the HDAC6 inhibitor and the aurora kinase inhibitor are administered at approximately the same time. 3. The method of claim 1 , wherein the HDAC6 inhibitor and the aurora kinase inhibitor are administered at different times. 4. A method of decreasing cell growth and viability, comprising contacting the cell with a pharmaceutical combination of any one of claim 1 , wherein the cell is a myeloma cell or a lymphoma cell.
Assignees
Inventors
Classifications
Antineoplastic agents · CPC title
Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin · CPC title
ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine · CPC title
not condensed and containing further heterocyclic rings, e.g. timolol · CPC title
- A61K31/505Primary
Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US11357776B2 cover?
- The present disclosure relates to a pharmaceutical combination comprising (a) a histone deacetylase 6 inhibitor and (b) an aurora kinase inhibitor, including combined preparations and pharmaceutical compositions thereof; uses of such combination in the treatment or prevention of cancer; and methods of treating or preventing cancer in a subject comprising administering a therapeutically effectiv…
- Who is the assignee on this patent?
- Acetylon Pharmaceuticals Inc
- What technology area does this patent fall under?
- Primary CPC classification A61K31/505. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue Jun 14 2022 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 1 related publication on this page (citations in our corpus or others sharing the same primary CPC).